Registration and prospectus / 60 Degrees Pharmaceuticals, Inc. | Tables in SEC filings

SXTP 60 Degrees Pharmaceuticals, Inc.

IPO registration (amended)

Country

Mark

Status

Application Number

Date Filed

Registration Date

Registration Number

BIR Ref Number

Due Date

Due Date Description

Australia

KODATEF

Registered

1774631

2-Jun-16

6/2/2016

1774631

0081716-000029

2-Jun-26

Renewal Due

Canada

KODATEF

Registered

1785098

1-Jun-16

11/26/2019

TMA1,064,371

0081716-000028

26-Nov-29

Renewal Due

Canada

ARAKODA

Registered

1899317

15-May-18

8/20/2020

TMA1,081,180

0081716-000053

20-Aug-30

Renewal Due

China

KODATEF

Registered

20842242

2-Aug-16

9/28/2017

20842242

0081716-000035

27-Sep-27

Renewal Due

European Union

KODATEF

Registered

15508872

3-Jun-16

9/21/2016

15508872

0081716-000034

3-Jun-26

Renewal Due

European Union

ARAKODA

Registered

17900852

16-May-18

9/20/2018

17900852

0081716-000054

16-May-28

Renewal Due

Israel

KODATEF

Registered

285476

6-Jun-16

6/6/2016

285476

0081716-000033

6-Jun-26

Renewal Due

New Zealand

KODATEF

Registered

1044407

7-Jun-16

12/8/2016

1044407

0081716-000031

6-May-26

Renewal Due

Russian Federation

KODATEF

Registered

2016720181

6-Jun-16

7/10/2017

623174

0081716-000032

6-Jun-26

Renewal Due

Singapore

KODATEF

Registered

40201707950V

2-May-17

11/8/2017

40201707950V

0081716-000040

2-May-27

Renewal Due

United Kingdom

ARAKODA

Registered

17900852

16-May-18

9/20/2018

UK00917900852

0081716-000054

16-May-28

Renewal Due

United Kingdom

KODATEF

Registered

15508872

3-Jun-16

9/21/2016

UK009015508872

0081716-000072

3-Jun-26

Renewal Due

United States of America

TQ 100 & TABLET DESIGN

Registered

87608493

14-Sep-17

9/11/2018

5562900

0081716-000037

11-Sep-24

Section 8 & 15 Due

United States of America

ARAKODA

Registered

87688137

16-Nov-17

12/31/2019

5950691

0081716-000050

31-Dec-25

Section 8 & 15 Due

United States of America

KODATEF

Allowed - 02/16/2021

90072885

24-Jul-20

0081716-000069

16-Aug-23

Statement of Use/3rd Extension of Time Due

Description	Amount
Working Capital and General Corporate Purposes	$	2,411,726
Debt Repayment	$	1,925,000
Research and Development (clinical trials and related activities)	$	3,400,000
Anticipated Research and Development Tax Credits	$	1,400,000
Total	$	6,336,726

	Three Months Ended
	March 31,
Consolidated Statements of Operations Data:	2023			2022
Product revenues – net of discounts and rebates		100.00	%		100.00	%
Cost of revenues		425.81			191.68
Gross loss		(325.81)			(91.68)
Research revenues		24.99			249.12
Net revenue		(300.82)			157.44
Operating expenses:
Research and development		722.07			134.10
General and administrative expenses		4,513.24			371.50
Total operating expenses		5,235.31			505.60
Loss from operations		(5,536.13)			(348.16)
Interest and other income (expense), net:
Interest expense		(6,647.04)			(1,620.91)
Change in fair value of derivative liabilities		(29.90)			-
Loss on debt extinguishment		(4,891.03)			-
Change in fair value of promissory note		1,947.45			-
Other income		3.44			39.83
Total interest and other income (expense), net		(9,590.08)			(1,581.08)
Loss from operations before provision for income taxes		(15,126.21)			(1,929.24)
Provision for income taxes		0.37			0.53
Net loss including noncontrolling interest		(15,126.58)			(1,929.77)
Net gain (loss) noncontrolling interest		14.72			10.28
Net loss - attributed to 60 Degrees Pharmaceuticals Inc		(15,141.30)			(1,940.05)

Comprehensive loss:
Net loss		(15,126.58)			(1,929.77)
Unrealized foreign currency translation gain (loss)		(7.51)			205.34
Total comprehensive loss		(15,134.09)			(1,724.43)

Net gain (loss) – noncontrolling interest		14.72			10.28
Unrealized foreign currency translation gain from noncontrolling interest		0.00			0.00
Comprehensive loss - attributed to 60 Degrees Pharmaceuticals, Inc.		(15,148.81)			(1,734.71)

	Payments Due By Period
			Less than						More than
	Total		1 year		1-3 years		4-5 years		5 years
Principal obligations on the debt arrangements	$	8,997,383	$	8,847,383	$	-	$	1,574	$	148,426
Interest obligations on the debt arrangements		15,097,215		15,097,215		-		-		-
Operating leases		13,000		13,000		-		-		-
Purchase obligations		1,338,668		1,338,668		-		-		-
Total	$	25,446,266	$	25,296,266	$	-	$	1,574	$	148,426

Table search / Registration and prospectus / 60 Degrees Pharmaceuticals, Inc.

365 results

Top filers

Top filing types

Recent filing years